Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director · Chief Executive Officer | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 666,568 |
Ending reported balance
After 2026-10-01 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 30,000 · Balance 696,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. Row 2 · 2026-10-01 · Sale · Disposed 3,525 · Balance 693,043 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-01 · Sale · Disposed 5,506 · Balance 687,537 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-10-01 · Sale · Disposed 4,876 · Balance 682,661 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-10-01 · Sale · Disposed 7,601 · Balance 675,060 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-10-01 · Sale · Disposed 8,230 · Balance 666,830 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-10-01 · Sale · Disposed 262 · Balance 666,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2029-11-13 | Direct | 60,000 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 30,000 · Balance 60,000 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F8: The shares underlying this stock option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The shares underlying this stock option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 01:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-26-410839 · ownership.xml · derivative · entry 8 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F8 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 01:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 262 | $116.12 | $30,423.44 |
DisclosureSEC source: 0001193125-26-410839 · ownership.xml · nonDerivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,568 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 01:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,230 | $115.40 | $949,742.00 |
DisclosureSEC source: 0001193125-26-410839 · ownership.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,830 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 01:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,601 | $114.43 | $869,782.43 |
DisclosureSEC source: 0001193125-26-410839 · ownership.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 675,060 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 01:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,876 | $113.24 | $552,158.24 |
DisclosureSEC source: 0001193125-26-410839 · ownership.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 682,661 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 01:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,506 | $112.42 | $618,984.52 |
DisclosureSEC source: 0001193125-26-410839 · ownership.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 687,537 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 01:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,525 | $111.44 | $392,826.00 |
DisclosureSEC source: 0001193125-26-410839 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 693,043 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 01:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 30,000 | $2.08 | $62,400.00 |
DisclosureSEC source: 0001193125-26-410839 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 696,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 00:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,441 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-26-297817 · ownership.xml · derivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,284 Underlying: Common Stock · 4,441 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 00:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,559 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-26-297817 · ownership.xml · derivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 45,559 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 00:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 50,000 | $119.00 | $5,950,000.00 |
DisclosureSEC source: 0001193125-26-297817 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,568 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 00:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 50,000 | $2.08 | $104,000.00 |
DisclosureSEC source: 0001193125-26-297817 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 716,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-26-295088 · ownership.xml · derivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,559 Underlying: Common Stock · 80,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F8 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,336 | $116.56 | $388,840.82 |
DisclosureSEC source: 0001193125-26-295088 · ownership.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,568 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.29 to $116.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 44,050 | $115.69 | $5,096,069.62 |
DisclosureSEC source: 0001193125-26-295088 · ownership.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 669,904 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.31 to $116.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 24,105 | $114.96 | $2,771,002.33 |
DisclosureSEC source: 0001193125-26-295088 · ownership.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 713,954 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.29 to $115.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,626 | $113.98 | $755,203.65 |
DisclosureSEC source: 0001193125-26-295088 · ownership.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 738,059 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.36 to $114.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,883 | $112.80 | $212,411.06 |
DisclosureSEC source: 0001193125-26-295088 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 744,685 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.28 to $113.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 80,000 | $2.08 | $166,400.00 |
DisclosureSEC source: 0001193125-26-295088 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 746,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F2 · balance_after: This number includes 373 shares acquired under the Registrant's employee stock purchase plan. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 21:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-26-192146 · ownership.xml · derivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,559 Underlying: Common Stock · 30,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F5 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 21:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 936 | $82.45 | $77,173.20 |
DisclosureSEC source: 0001193125-26-192146 · ownership.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,195 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.30 to $83.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 21:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 12,059 | $81.70 | $985,220.30 |
DisclosureSEC source: 0001193125-26-192146 · ownership.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 667,131 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.23 to $82.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 21:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 17,005 | $80.74 | $1,372,983.70 |
DisclosureSEC source: 0001193125-26-192146 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 679,190 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.23 to $81.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 21:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 30,000 | $2.08 | $62,400.00 |
DisclosureSEC source: 0001193125-26-192146 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 696,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $90.10 | $0.00 |
DisclosureSEC source: 0001193125-26-091980 · ownership.xml · derivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2036-03-01 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| February 25, 2026 Filed Feb 25, 2026 22:24 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-26-072155 · ownership.xml · derivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,559 Underlying: Common Stock · 30,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F6 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| February 25, 2026 Filed Feb 25, 2026 22:24 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8 | $93.49 | $747.92 |
DisclosureSEC source: 0001193125-26-072155 · ownership.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,195 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| February 25, 2026 Filed Feb 25, 2026 22:24 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,501 | $92.81 | $139,307.81 |
DisclosureSEC source: 0001193125-26-072155 · ownership.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,203 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.20 to $93.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2026 Filed Feb 25, 2026 22:24 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,293 | $91.76 | $302,165.68 |
DisclosureSEC source: 0001193125-26-072155 · ownership.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 667,704 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.295 to $92.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2026 Filed Feb 25, 2026 22:24 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,434 | $90.39 | $491,179.26 |
DisclosureSEC source: 0001193125-26-072155 · ownership.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 670,997 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.16 to $90.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2026 Filed Feb 25, 2026 22:24 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 19,764 | $89.78 | $1,774,411.92 |
DisclosureSEC source: 0001193125-26-072155 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 676,431 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.16 to $90.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2026 Filed Feb 25, 2026 22:24 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 30,000 | $2.08 | $62,400.00 |
DisclosureSEC source: 0001193125-26-072155 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 696,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:40 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,118 | $0.00 Strike: $32.07 | $0.00 |
DisclosureSEC source: 0001193125-26-004641 · ownership.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,882 Underlying: Common Stock · 3,118 shares Expires 2033-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:40 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 3,118 | $32.07 | $99,994.26 |
DisclosureSEC source: 0001193125-26-004641 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 666,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2025 Filed Dec 31, 2025 22:23 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-25-338415 · ownership.xml · derivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,559 Underlying: Common Stock · 30,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 31, 2025 Filed Dec 31, 2025 22:23 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,014 | $78.52 | $472,211.46 |
DisclosureSEC source: 0001193125-25-338415 · ownership.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 663,077 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.44 to $78.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2025 Filed Dec 31, 2025 22:23 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 23,986 | $77.95 | $1,869,727.89 |
DisclosureSEC source: 0001193125-25-338415 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 669,091 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.44 to $78.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2025 Filed Dec 31, 2025 22:23 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 30,000 | $2.08 | $62,400.00 |
DisclosureSEC source: 0001193125-25-338415 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 693,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,595 | $0.00 Strike: $38.53 | $0.00 |
DisclosureSEC source: 0001193125-25-323092 · ownership.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,505 Underlying: Common Stock · 2,595 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,595 | $38.53 | $99,985.35 |
DisclosureSEC source: 0001193125-25-323092 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 663,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-25-311504 · ownership.xml · derivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,559 Underlying: Common Stock · 100,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 100,000 | $89.17 | $8,917,000.00 |
DisclosureSEC source: 0001193125-25-311504 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 660,482 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 100,000 | $2.08 | $208,000.00 |
DisclosureSEC source: 0001193125-25-311504 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 760,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| October 29, 2025 Filed Oct 29, 2025 21:19 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-25-256673 · ownership.xml · derivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,559 Underlying: Common Stock · 30,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F5 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| October 29, 2025 Filed Oct 29, 2025 21:19 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,627 | $61.46 | $222,906.72 |
DisclosureSEC source: 0001193125-25-256673 · ownership.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 660,482 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.37 to $61.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2025 Filed Oct 29, 2025 21:19 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 24,511 | $61.02 | $1,495,626.90 |
DisclosureSEC source: 0001193125-25-256673 · ownership.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 664,109 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.37 to $61.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2025 Filed Oct 29, 2025 21:19 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,862 | $59.72 | $111,203.30 |
DisclosureSEC source: 0001193125-25-256673 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 688,620 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.35 to $60.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2025 Filed Oct 29, 2025 21:19 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 30,000 | $2.08 | $62,400.00 |
DisclosureSEC source: 0001193125-25-256673 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 690,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| September 16, 2025 Filed Sep 16, 2025 20:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-25-204997 · ownership.xml · derivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,559 Underlying: Common Stock · 30,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| September 16, 2025 Filed Sep 16, 2025 20:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 30,000 | $49.00 | $1,470,000.00 |
DisclosureSEC source: 0001193125-25-204997 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 660,482 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.